Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial-Reference-Cited by-同舟云学术

Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial

Published:2015-06 Issue:9985 Volume:385 Page:2355-2362
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Cox Timothy M,Drelichman Guillermo,Cravo Renata,Balwani Manisha,Burrow Thomas Andrew,Martins Ana Maria,Lukina Elena,Rosenbloom Barry,Ross Leorah,Angell Jennifer,Puga Ana Cristina

Funder

UK Medical Research Council and at Mount Sinai Hospital

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Gaucher disease: phenotypic and genetic variation;Grabowski,2006

2. Gaucher disease: review of the literature;Chen;Arch Pathol Lab Med,2008

3. Phenotype, diagnosis, and treatment of Gaucher's disease;Grabowski;Lancet,2008

4. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis;Mistry;Br J Haematol,2009

5. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy;Deegan;Medicine (Baltimore),2011

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-in-human single-dose study of nizubaglustat, a dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramidase: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending and multiple doses in healthy adults;Molecular Genetics and Metabolism;2024-01

2. Effectiveness and Safety of Eliglustat Treatment in Gaucher Disease: Real-life Unicentric Experience;Clinical Therapeutics;2023-11

3. Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study;Molecular Genetics and Metabolism;2023-11

4. Gaucher Disease Types I and III Responded Well to Substrate Reduction Therapy Using Eliglustat;Internal Medicine;2023-10-15

5. Joint manifestations revealing inborn metabolic diseases in adults: a narrative review;Orphanet Journal of Rare Diseases;2023-08-10